Note: This article is for educational and informational purposes only. Any studies referenced relate solely to laboratory and scientific models. Peptides discussed here are for Research Use Only. They are not approved drugs, supplements, or cosmetic products and are not for human or veterinary use.

Quick Context

ARA-290 is an 11 amino acid peptide engineered from a specific region of erythropoietin (EPO). It was designed to focus on tissue protective and repair signaling while avoiding EPO’s red blood cell stimulating effects, which can introduce risk when misused.

In published research, ARA-290 most commonly appears in peptide research regarding inflammation driven tissue stress, nerve discomfort patterns, and small fiber neuropathy, including sarcoidosis associated small fiber neuropathy. Additional exploratory work includes diabetic neuropathy and diabetic macular edema.

ARA-290 is studied as a repair signal rather than a simple symptom masker. Much of the research focuses on the inflammatory environment surrounding injured or irritated tissue, especially small nerve fibers.

What is ARA-290?

Also called cibinetide

In scientific literature and clinical trial records, ARA-290 is commonly referred to as cibinetide. Searching under this name often yields more complete research results.

Derived from EPO, without blood building effects

Erythropoietin is best known for increasing red blood cell production. ARA-290 was engineered to preserve tissue protective signaling pathways while avoiding erythropoiesis, which is why it is consistently described as non erythropoietic in the literature.

How ARA-290 is Thought To Work

The innate repair receptor concept

ARA-290 is believed to activate a receptor complex known as the innate repair receptor. This involves the EPO receptor paired with the beta common receptor (CD131). This receptor configuration appears to become more active in response to tissue injury or metabolic stress and is associated with repair oriented signaling.

What researchers associate with this signaling

• Reduction of pro inflammatory signaling
• Cell protection pathways that limit stress related damage
• Improved tissue resilience under inflammatory or oxidative conditions
• Immune modulation that favors recovery over ongoing damage

The research narrative around ARA-290 focuses on calming the body’s internal repair conversation, especially in tissues trapped in chronic inflammatory loops.

Primary Areas of Human Research

Sarcoidosis associated small fiber neuropathy

The strongest body of human research involves sarcoidosis associated small fiber neuropathy. Studies include randomized clinical trials assessing symptom severity alongside objective measures such as corneal nerve fiber density.

Published findings describe improvements in neuropathic symptoms and increases in corneal nerve fiber abundance, suggesting a potential effect on nerve integrity rather than sensation alone.

Type 2 diabetes and painful neuropathy

ARA-290 has also been evaluated in individuals with type 2 diabetes experiencing painful neuropathy. Clinical trial reporting described improvements in neuropathic pain outcomes and noted changes in metabolic markers, framed as signals that justified further investigation.

Diabetic macular edema

Exploratory phase 2 research examined cibinetide in diabetic macular edema. The study described the treatment course as safe and reported changes in vision related measures and retinal thickness, prompting calls for additional research.

Preclinical and Mechanistic Research Themes

Immune modulation

Mechanistic studies show interest in how cibinetide influences innate immune cell behavior, aligning with broader goals of reducing tissue damaging inflammation.

Kidney and tissue protection

ARA-290 has been examined in tissue stress models such as chemotherapy associated kidney injury. Researchers describe anti inflammatory and cell protective signaling as part of the proposed mechanism.

Wound healing in metabolic stress

Because diabetes is associated with impaired healing, cibinetide has been studied in diabetic wound models where activation of repair signaling pathways may support improved healing dynamics.

Safety Observations From Human Studies

Across published clinical studies, cibinetide is generally described as well tolerated during study periods and consistently noted for its lack of erythropoietic activity.

Short term safety findings do not establish long term safety or suitability outside controlled research environments.

Where ARA-290 Fits In Peptide Discussions

ARA-290 is often discussed alongside peptides explored for inflammation control, nerve comfort, and tissue recovery. Its distinguishing feature in the literature is its focus on repair signaling rather than symptom suppression.

ARA-290 is frequently framed as a tone setter for recovery, helping tissues shift from prolonged alarm toward repair.

References

Brines M, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.
https://pmc.ncbi.nlm.nih.gov/articles/PMC4365069/

Culver DA, et al. Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small fiber neuropathy.
https://iovs.arvojournals.org/article.aspx?articleid=2625918

Heij L, et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy.
https://link.springer.com/article/10.2119/molmed.2012.00332

Dahan A, et al. Targeting the innate repair receptor to treat neuropathy.
https://pmc.ncbi.nlm.nih.gov/articles/PMC5741312/

Nairz M, et al. Cibinetide dampens innate immune cell functions and limits inflammatory tissue damage.
https://www.nature.com/articles/s41598-017-13046-3

Lois N, et al. A Phase 2 clinical trial of cibinetide for the treatment of diabetic macular edema.
https://pmc.ncbi.nlm.nih.gov/articles/PMC7408632/

ClinicalTrials.gov. Cibinetide (ARA-290) in sarcoidosis small fiber neuropathy.
https://clinicaltrials.gov/study/NCT02039687